Trobix Bio Secures Continued Funding from the Israel Innovation Authority

Continued Financing is a Testament of the Israeli Government's Endorsement for the Significant Traction Reached in Developing the Groundbreaking Technology of Trobix Bio

Netanya, Israel, March 15, 2022

Netanya, Israel. Trobix Innovation Ltd. (<u>Trobix Bio</u>), an Israeli-based biotechnology company developing novel microbiome-based therapeutics to treat severe unmet needs, announces that the Israel Innovation Authority (IIA), the lead R&D supporting arm of the Israeli government, recently approved a non-dilutive grant under its "R&D fund Program", in the total amount to be received of close to \$1M. This grant will be used to advance the company's TBX™ platform technology and to further the development of its lead product, TBX101.

"The significant traction made over the past year by the company has paved the way to further financial support from the IIA, which we are grateful for", said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. "This recent funding brings our total funding from non-dilutive sources to ~\$2M, leveraging our investors funds to significantly advance the development of our lead product, TBX101", he added.

About Trobix Bio

Trobix Bio is an Israeli-based pre-clinical company, empowering engineered phages using CRISPR and synthetic biology to modify microbiome traits and to develop life-changing therapeutics for better medicine.

Trobix Bio TBX[™] platform technology combines proprietary molecular engineering and computational algorithms to develop CRISPR-based synthetic phages. Trobix Bio is leveraging its TBX technology to develop a diverse innovative microbiome-based therapeutic pipeline in high unmet need areas that include anti-microbial resistance, oncology, and gut inflammation.

Trobix Bio offers a game changing value proposition, a unique platform technology with a strong IP portfolio, and a rich pipeline of innovative microbiome-based therapeutics with strong pre-clinical proof-of-concept data.

For further information, please contact:

Dr. Adi Elkeles CEO & Co-Founder Trobix Bio

Tel: +972-54-6402333 Email: <u>adie@trobix.bio</u>